TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: change in sensory perception score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Lateropulsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of bicarbonate concentration in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes of base excess concentration in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of invasive mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Numeric Pain Rating Scale (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of common winter infectious diseases
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of 30 Day Readmission
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Reported Outcomes Measurement Information System (PROMIS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Functional, Communicative and Critical Health Literacy (FFFHL) scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Medical Interview Satisfaction Scale (MISS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Consumer Assessment of Healthcare Providers and Systems (CAHPS) survey
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Oropharyngeal airway leak pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma PCSK9 Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower Extremity Skeletal Muscle Glucose Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of local and distant recurrences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline Amount of Fat Oxidation at 14 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fat Oxidation Rates at 1 Week Intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Diagnostic Adequacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isokinetic strength testing (peak torques)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isokinetic strength testing (ratios)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical measurements, ROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confidence in ability to consume calcium
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Actual calcium consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Circumference of each affected leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percent inhibition of serum thromboxane B2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: complete response rate (CRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of adverse events occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Perioperative morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTSD Check List (PCL) results
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Geometric Mean Titer (GMT) of Varicella-Zoster Virus (VZV) Antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Delivery Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Chronic Venous Insufficiency Questionnaire-20 (CIVIQ-20)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Photoplethysmograph (PPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Time within SpO2-interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in respiratory quotient (RQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in olfactory liking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: percent change in tumor radioactivity uptake and retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Symptoms of attention deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Wound Occurrences
Endpoint domain: Adverse events/effects
Primary endpoint: Pain scores by coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appearance of free fatty acids in the duodenum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in airflow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in the cross-sectional area of the nasal passage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in Uveal Melanoma Tumor Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of infants with hypotension requiring inotropes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum tolerated dosage (MTD) and/or recommended phase 2 dosage (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Functional Independence Measure - Locomotor Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Baseline Aerobic Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Treatment-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of Treatment-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: High-intensity signal of the oculomotor nerve on MRI T2 sequence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Blood Stream Infection Within 1 Week of Surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Titer of influenza antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diameter and depth of ablation and/or coagulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: NYHA Functional Classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiovascular Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Hemodynamic Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arteriovenous fistula (AVF) Thrill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with primary pulmonary coccidioidomycosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sinonasal Outcome Test - 22
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Expert Panel Overall Assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area under the curve of free moxifloxacin fecal concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days of detectable milk vitamin D concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Sickle Cell Self-Efficacy Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Wake Forest Trust in the Medical Profession Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Seidman Sickle Cell Knowledge Quiz scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean Change in Severity of Alopecia Tool (SALT) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Dermatomes of Sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Development of pregnancy-induced hypertension (PIH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Mean Change on Busso Hand Volume Severity Scale (BHVSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥ 1-point Change on Busso Hand Volume Severity Scale (BHVSS), by Hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥ 1-point Change on Busso Hand Volume Severity Scale (BHVSS), by Subject
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adenoma miss rate in the proximal colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Participants With Spleen Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Symptom Response
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline PTSD Checklist- Civilian (PCL-C)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline Patient Health Questionnaire 9 Item Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline Alcohol Use Disorders Identification
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline Short Form (SF)-12/36 Physical Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Progression-free Survival at 5 Years
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival at 5 Years
Endpoint domain: Mortality/survival
Primary endpoint: Peripapillary retinal nerve fibre layer thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macular ganglion cell complex thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subfoveal and perifoveal choroidal thicknesses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Choroidal vascularity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Count of participants who discontinued single ascending dose (SAD) for safety reasons
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Adverse Events (AE) for a single dose taken after food ingestion
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of abnormal ECG changes from baseline (categorized as clinical Adverse Events (AEs)) for single ascending dose (SAD)
Endpoint domain: Adverse events/effects
Primary endpoint: Differences in protein levels in EOS-preeclampsia patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in memory after receiving treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in attention after receiving treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in working memory after receiving treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in executive function, set-shifting after receiving treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in executive function, verbal fluency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent of referred who consent and meet study criteria
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent of 12 sessions completed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Counts of premature termination of intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Self-report of Credibility/Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-report of User Experience
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of biopsy-proven kidney rejection episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Weighted Mean Change From Baseline in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Survival rate of zirconia ceramic RBFDs
Endpoint domain: Mortality/survival
Primary endpoint: 30-day rate of major adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Intestinal wall pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastrointestinal vessel pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intestinal diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Extraintestinal pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Hepatic histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of Participants Adhere to the Assigned Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total Number of Participants Withdraw From the Study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total Number of Participants Completed the Study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patients survival
Endpoint domain: Mortality/survival
Primary endpoint: smoking reduction rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence And Severity Of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: number of patients safely completing the study
Endpoint domain: Mortality/survival
Primary endpoint: total number of self-reported exercise sessions attempted divided by the total number of exercise sessions prescribed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding on probing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: change in Knee Society Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NYHA Functional Classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of Bortezomib in treating cGVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Bortezomib in treating cGVHD
Endpoint domain: Adverse events/effects
Primary endpoint: ESS change (Epworth Sleepiness Scale)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Mean Economic Cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in ASIALEMS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in Perceived Primary Control Scale for Children
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Perceived Secondary Control Scale for Children
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of postoperative severe skin reactions (blisters)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean difference of oxidized-LDL gene polymorphism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effect-site concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with SpO2 <90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fasting S-phenylalanine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: COPD diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood levels of drugs and their metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall survival on ciclib
Endpoint domain: Mortality/survival
Primary endpoint: Progression-free survival on ciclib
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of treatment related toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Forced expiratory volume in 1 second (FEV1) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in High-Density-Lipoproteins concentrations (HDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Iron Deficiency Anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants who complete screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with positive, high-risk human papillomavirus (HPV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of participants with cervical intraepithelial neoplasia (CIN2)+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Lenalidomide toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Lenalidomide tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Lenalidomide efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erectile dysfunction
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Cough peak expiratory flow (cPEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Insulin sensitivity ('M' value)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Functioning on the Active Straight Leg Rise (ASLR) Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Fear of COVID-19
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reduction of left ventricular hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Brunininks-Oseretsky Test of Motor Proficiency II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Straight leg raising test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants Completing Qualitative Interviews
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Physical disability RMDQ
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to Hospitalization or Death
Endpoint domain: Mortality/survival
Primary endpoint: Change in Heart Failure Disease Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incident dementia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: persistent physical disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ratio of Maintenance of target Hb concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Child IQ
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Adipogenic capacity of preadipocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of positive PET scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of residents using validation tool
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in left ventricular relaxation indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in pressure-half time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the sum of ST segment deviations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Walking pain assessment scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of NAA and glutamate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Completion of study by all subjects
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Haemodynamic stabilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients with 50% or Greater Reduction in Antihypertensive Medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of reported events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VO2 at AT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilation Efficiency Slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen Uptake Efficiency Slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal graft rejection
Endpoint domain: Adverse events/effects